SCHEMBL20893409

SCHEMBL20893409

CCOC(=O)c1oc2cc(F)ccc2c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 5/20 0.52
MAPT P10636 4/20 0.52
HSD17B10 Q99714 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
TSHR P16473 2/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
RAB9A P51151 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
NPC1 O15118 2/20 0.51
AHR P35869 1/20 0.51
NR1H2 P55055 1/20 0.51
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18394631 0.89 KDM4E (0.67) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL20893375 0.89 MAPT (0.62) KDM4EALDH1A1MAPTTSHRRAB9A
SCHEMBL30136795 0.89 MAPT (0.62) KDM4EALDH1A1MAPTTSHRRAB9A
SCHEMBL914799 0.87 KDM4E (0.47) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL25205148 0.86 KDM4E (0.46) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL31015899 0.86 KDM4E (0.46) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL20893358 0.85 L3MBTL1 (0.61) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL10739672 0.84 ALDH1A1 (0.70) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL20893367 0.83 MCL1 (0.67) KDM4EALDH1A1MAPTHSD17B10KMT2A
SCHEMBL20357978 0.83 KDM4E (0.58) KDM4EALDH1A1MAPTHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641908-B Five-membered heterocyclic [3,4-d ] pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2021-11-19 CN disclosed
US-20190135818-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2019-05-09 US disclosed
EP-3470415-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135818-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF FGFR1, FGFR3, FGFR4 KDM4E 712/4885ALDH1A1 697/4885MAPT 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.